A Study to Evaluate the Safety and Efficacy of Ex Vivo Expanded Autologous Immune Killer Cells (IKC) in Stage IV Non-small Cell Lung Cancer (NSCLC) in Patients Who Failed Chemotherapy or Target Therapy
Clinical trial NCT03499834 · COMPLETED
Trial details
- NCT number
- NCT03499834
- Sponsor
- Ivy Life Sciences, Co., Ltd
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-12-05
- Primary completion
- 2020-02-16
- Enrollment
- 26
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.